Powered by

That generic Advair you've been expecting for months? It'll come, but let's talk other products, Mylan says

Nov 06, 2018 - FiercePharma

After the FDA shot down Mylan's generic Advair for the second time in June, executives said they addressed the “minor deficiencies” and an approval should follow in mid-October. Aweek into November, the green light is nowhere to be seen—and the company had toagain reassure investors.

Evaluation of its copy of GlaxoSmithKline's asthma blockbuster is “in the final stage of labeling review,” said company president Rajiv Malik duringthe company'sthird-quarter earnings call. “We con...